Обновленные рекомендации EULAR 2025 по ведению пациентов с синдромом/болезнью Бехчета

Статья посвящена обновленным рекомендациям Европейского альянса ревматологических ассоциаций (EULAR, European Alliance of Associations for Rheumatology ) 2025 года по ведению пациентов с синдромом/ болезнью Бехчета, которые включают 5 основополагающих принципов и 12 рекомендаций, касающихся лечения различных органных поражений, а также комментарии к ним. Рассмотрены методология создания рекомендаций, а также нерешенные вопросы ведения пациентов с синдромом/болезнью Бехчета, которые планируется исследовать в будущем.

1. Yazici H, Hatemi G, Yazici Y. Can we cure Behçet syndrome? Curr Opin Immunol. 2025;95:102597. doi: 10.1016/j.coi.2025.102597

2. Emmi G, Bettiol A, Hatemi G, Prisco D. Behçet‘s syndrome. Lancet. 2024;403(10431):1093-1108. doi: 10.1016/S01406736(23)02629-6

3. Saadoun D, Bodaghi B, Cacoub P. Behçet‘s syndrome. N Engl J Med. 2024;390(7):640-651. doi: 10.1056/NEJMra2305712

4. Ozguler Y, Esatoglu SN, Hatemi G. Current pharmacological solutions for Behçet‘s syndrome. Expert Opin Pharmacother. 2023;24(2):221-231. doi: 10.1080/14656566.2022.2155047

5. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al.; EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656-1662. doi: 10.1136/ard.2007.080432

6. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225

7. EULAR SOPs – Standard Operating Procedures for Task Forces 2025. URL: https://www.eular.org/web/static/lib/pdfjs/web/viewer.html?file=https://www.eular.org/document/download/1288/44fd21f5-69ff-449e-a959-c1398468bfe1/1198 (Accessed 18th March 2026).

8. Hatemi G, Ramiro S, Ozguler Y, Esatoglu SN, Tomasson G, Barete S, et al. EULAR recommendations for the management of Behçet’s syndrome: 2025 update. Ann Rheum Dis. 2026;85(6):1010-1025. doi: 10.1016/j.ard.2026.02.009

9. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898

10. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359-368. doi: 10.2147/CLEP.S66677

11. Ozguler Y, Esatoglu SN, Tomasson G, Falzon L, Barete S, Bettiol A, et al. Management of major organ involvement in Behcet syndrome: A systematic literature review informing, the 2025 update of the EULAR recommendations. EULAR Rheumatology Open. 2026;2(2):100152. doi: 10.1016/j.ero.2026.02.019

12. Esatoglu SN, Ozguler Y, Tomasson G, Falzon L, Barete S, Bettiol A, et al. Management of mucocutaneous and joint involvement of Behcet’s syndrome: A systematic literature review informing the 2025 update of the EULAR recommendations. EULAR Rheumatology Open. 2026;2(2):100150. doi: 10.1016/j.ero.2026.02.017

13. Gazel Ü, Kocakaya D, Hicret Topçu İ, Ömer Karataş H, Karabacak M, Atagündüz MP, et al. Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: A case series and review of the literature. Turk J Med Sci. 2021;51(4):1689-1694. doi: 10.3906/sag-2010-311

14. Burleigh A, Omoyinmi E, Papadopoulou C, Al-Abadi E, Hong Y, Price-Kuehne F, et al. Genetic testing of Behçet’s disease using next-generation sequencing to identify monogenic mimics and HLA-B*51. Rheumatology (Oxford). 2024;63(12):3457-3470. doi: 10.1093/rheumatology/kead628

15. Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019;381(20):1918-1928. doi: 10.1056/NEJMoa1816594

16. Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behçet’s syndrome – A phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510-1518. doi: 10.1056/NEJMoa1408684

17. Talarico R, Italiano N, Emmi G, Piga M, Cantarini L, Mattioli I, et al. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: A 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis. 2024 Oct 17:ard-2024-226113. doi: 10.1136/ard-2024-226113

18. Lopalco G, Morrone M, Venerito V, Cantarini L, Emmi G, Espinosa G, et al. Exploring relief for Behçet’s disease refractory oral ulcers: A comparison of TNF inhibitors versus apremilast. Rheumatology (Oxford). 2025;64(3):1302-1308. doi: 10.1093/rheumatology/keae274

19. London J, Régent A, Dion J, Jilet L, Jachiet M, Lidove O, et al. Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial. J Am Acad Dermatol. 2022;87(3):681-684. doi: 10.1016/j.jaad.2021.11.045

20. Mirouse A, Barete S, Desbois AC, Comarmond C, Sène D, Domont F, et al.; French Behçet’s Network. Long-term outcome of ustekinumab therapy for Behçet’s disease. Arthritis Rheumatol. 2019;71(10):1727-1732. doi: 10.1002/art.40912

21. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281-285. doi: 10.1056/NEJM199002013220501

22. Braun-Moscovici Y, Tavor Y, Markovits D, Toledano K, Rozin A, Nahir MA, et al. The effects of adalimumab in Behçet disease patients on clinical manifestations and on pro-inflammatory cytokines milieu: Long-term follow-up. Isr Med Assoc J. 2020;22(5):289-293.

23. Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet‘s disease: A pilot double-blind controlled study. Int J Rheum Dis. 2017;20(9):1269-1276. doi: 10.1111/1756185X.13095

24. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet‘s disease: A comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593-597. doi: 10.1093/rheumatology/keq366

25. Tao T, Yang S, He D, Li Z, Chen B, Zhu L, et al. Intravitreal dexamethasone implants facilitate the management of refractory Behçet’s uveitis with vasculitis. Clin Immunol. 2023;251:109633. doi: 10.1016/j.clim.2023.109633

26. Ghassemi F, Mirak SA, Chams H, Sabour S, Ahmadabadi MN, Davatchi F, et al. Characteristics of macular edema in Behcet disease after intravitreal bevacizumab injection. J Ophthalmic Vis Res. 2017;12(1):44-52. doi: 10.4103/jovr.jovr_254_15

27. Yang S, Huang Z, Hu Y, Zhang J, Liu X, Li H, et al. The efficacy of adalimumab as an initial treatment in patients with Behçet’s retinal vasculitis. Front Pharmacol. 2021;12:609148. doi: 10.3389/fphar.2021.609148

28. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932-943. doi: 10.1056/NEJMoa1509852

29. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183-1192. doi: 10.1016/S0140-6736(16)31339-3

30. Zhong Z, Deng D, Gao Y, Bu Q, Dai L, Feng X, et al. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet’s disease already on corticosteroid therapy: A randomised, open-label, head-to-head trial. Lancet Rheumatol. 2024;6(11):e780-e790. doi: 10.1016/S2665-9913(24)00194-2

31. Barroso-García N, Martín-Varillas JL, Ferraz-Amaro I, Sánchez- Bilbao L, Martín-Gutiérrez A, Adán A, et al. Comparative study of adalimumab, infliximab and certolizumab pegol in the treatment of cystoid macular edema due to Behçet’s disease. J Clin Med. 2024;13(23):7388. doi: 10.3390/jcm13237388

32. Barroso-García N, Atienza-Mateo B, Ferraz-Amaro I, Prieto-Peña D, Beltrán E, Adán A, et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet’s disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153. doi: 10.1016/j.semarthrit.2022.152153

33. Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: National multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081-2089. doi: 10.1002/art.41026

34. Mesen S, Ozer MD, Batur M. Comparative results of use and switching of anti-TNF-alpha agents in adult Behçet’s uveitis. Indian J Ophthalmol. 2024;72(Suppl 3):S521-S528. doi: 10.4103/ IJO.IJO_2011_23

35. Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-α therapy for refractory uveitis associated with Behçet’s syndrome and sarcoidosis: A single center study of 131 patients. Ocul Immunol Inflamm. 2022;30(1):223-230. doi: 10.1080/09273948.2020.1791346

36. Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, et al. Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol. 2018;37(6):1715-1720. doi: 10.1007/s10067-018-4092-4

37. Takeuchi M, Usui Y, Namba K, Keino H, Takeuchi M, Takase H, et al. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study. Front Med (Lausanne). 2023;10:1095423. doi: 10.3389/fmed.2023.1095423

38. Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: A large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2. doi: 10.1186/s13075-018-1793-7

39. Ucar D, Bircan BE, Rustamli N, Batu Oto B, Hamuryudan V, Hatemi G, et al. Development of posterior uveitis in Behçet syndrome patients with vitreous cells at baseline. Ocul Immunol Inflamm. 2025;33(2):243-249. doi: 10.1080/09273948.2024.2383315

40. Tugal-Tutkun I. Behçet’s uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219-224. doi: 10.4103/0974-9233.58425

41. Shirahama S, Kaburaki T, Matsuda J, Tanaka R, Nakahara H, Komae K, et al. The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular Behçet’s disease patients. Ocul Immunol Inflamm. 2020;28(8):1166-1170. doi: 10.1080/09273948.2019.1641611

42. Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, et al. Infliximab for vascular involvement in Behçet’s syndrome. Clin Immunol. 2023;253:109682. doi: 10.1016/j.clim.2023.109682

43. Aksoy A, Yazici A, Omma A, Cefle A, Onen F, Tasdemir U, et al. Efficacy of TNFα inhibitors for refractory vascular Behçet’s disease: A multicenter observational study of 27 patients and a review of the literature. Int J Rheum Dis. 2020;23(2):256-261. doi: 10.1111/1756-185X.13778

44. Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, et al. Infliximab versus cyclophosphamide for severe Behçet’s syndrome. NEJM Evid. 2024;3(11):EVIDoa2300354. doi: 10.1056/EVIDoa2300354

45. Gaudric J, Jayet J, Saadoun D, Couture T, Ferfar Y, Davaine JM, et al. Factors influencing the recurrence of arterial involvement after surgical repair in Behçet disease. J Vasc Surg. 2020;72(5):1761-1769. doi: 10.1016/j.jvs.2020.01.076

46. Ozguler Y, Hatemi G, Cetinkaya F, Tascilar K, Hamuryudan V, Ugurlu S, et al. Clinical course of acute deep vein thrombosis of the legs in Behçet’s syndrome. Rheumatology (Oxford). 2020;59(4):799-806. doi: 10.1093/rheumatology/kez352

47. Emmi G, Vitale A, Silvestri E, Boddi M, Becatti M, Fiorillo C, et al. Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behçet’s syndrome: A retrospective study of seventy patients with vascular involvement. Arthritis Rheumatol. 2018;70(9):1500-1507. doi: 10.1002/art.40531

48. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet‘s disease: Immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27(2):201-205. doi: 10.1007/s10067-007-0685-z

49. Alibaz-Oner F, Karadeniz A, Ylmaz S, Balkarl A, Kimyon G, Yazc A, et al. Behçet disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94(6):e494. doi: 10.1097/MD.0000000000000494

50. Erol S, Gürün Kaya A, Arslan F, Hasanzade H, Daştan AO, Çiledağ A, et al. Does anticoagulation in combination with immunosuppressive therapy prevent recurrent thrombosis in Behçet’s disease? J Investig Med. 2024;72(4):387-391. doi: 10.1177/10815589241232368

51. Vautier M, Gallien Y, Emmi G, Bettiol A, Karadag O, Bolek EC, et al. Direct oral anticoagulant for venous thrombosis in Behçet’s syndrome. Autoimmun Rev. 2021;20(4):102783. doi: 10.1016/j.autrev.2021.102783

52. Aksoy A, Colak S, Yagiz B, Coskun BN, Omma A, Yildiz Y, Sari A, et al. Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet’s disease. J Vasc Surg Venous Lymphat Disord. 2021;9(6):1451-1459. doi: 10.1016/j.jvsv.2021.02.007

53. Abacar KY, Boncukcuoglu AE, Aksoy A, Kocakaya D, Cimsit C, Direskeneli H, et al. Anticoagulant treatment may decrease the relapse rate of pulmonary arterial involvement in Behçet’s disease. J Clin Rheumatol. 2024;30(8):303-308. doi: 10.1097/RHU.0000000000002137

54. Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: A strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348. doi: 10.1097/MD.0000000000003348

55. Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet’s syndrome refractory to the conventional treatment modalities: A case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129-S137.

56. Zou J, Cai JF, Ye JF, Guan JL. Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124014. doi: 10.1177/1759720X221124014

57. Liu J, Yu X, Wang Z, Liu W, Liu X, Wang X, et al. Baricitinib for the treatment of intestinal Behçet’s disease: A pilot study. Clin Immunol. 2023;247:109241. doi: 10.1016/j.clim.2023.109241

58. Desbois AC, Addimanda O, Bertrand A, Deroux A, Pérard L, Depaz R, et al. Efficacy of anti-TNFα in severe and refractory neuro-Behcet disease: An observational study. Medicine (Baltimore). 2016;95(23):e3550. doi: 10.1097/MD.0000000000003550

59. Wang X, Liu Y, Ao Y, Wang J, Liu J, Xu Y, et al. Infliximab for parenchymal neuro-Behçet’s syndrome: Case series and metaanalysis. Clin Exp Rheumatol. 2024;42(10):2040-2048. doi: 10.55563/clinexprheumatol/5lnkd4

60. Yalcin Kehribar D, Gunaydin S, Ozgen M. Infliximab therapy in parenchymal neuro-Behçet‘s disease: A single-center experience. Int J Rheum Dis. 2021;24(10):1302-1307. doi: 10.1111/1756185X.14209

61. Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. doi: 10.1212/NXI.0000000000000258

62. Rabia KE, Gizem G, Furkan S, Sanja G, Nihan CB, Yavuz P, et al. Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective study. Clin Rheumatol. 2024;43(10):3213-3221. doi: 10.1007/s10067-024-07118-9

63. Hirohata S, Kikuchi H, Sawada T, Kuwana M, Kawachi I, Kirino Y, et al. Effect of infliximab on chronic progressive neuro-Behçet’s disease: Influence of the timing of introduction on the patient outcome. Intern Med. 2024;63(4):481-486. doi: 10.2169/internalmedicine.1969-23

64. Khitri MY, Bartoli A, Maalouf G, Deroux A, Salvarani C, Emmi G, et al. Tocilizumab in Behçet disease: A multicenter study of 30 patients. J Rheumatol. 2023;50(7):916-923. doi: 10.3899/jrheum.221106

65. Arida A, Saadoun D, Sfikakis PP. IL-6 blockade for Behçet’s disease: Review on 31 anti-TNF naive and 45 anti-TNF experienced patients. Clin Exp Rheumatol. 2022;40(8):1575-1583. doi: 10.55563/clinexprheumatol/avhxp6

66. Karabulut Y. Use of non-TNF biologics for the treatment of neuro-Behçet’s disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab. Eur J Rheumatol. 2021;8(4):223-227. doi: 10.5152/eurjrheum.2021.20160

67. Liu J, Yan D, Wang Z, Yang Y, Zhang S, Wu D, et al. Tocilizumab in the treatment of severe and refractory parenchymal neuroBehçet’s syndrome: Case series and literature review. Ther Adv Musculoskelet Dis. 2020;12:1759720X20971908. doi: 10.1177/1759720X20971908

68. Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: Report of two cases. Rheumatology (Oxford). 2013;52(10):1923-1924. doi: 10.1093/rheumatology/ket130

69. Hatemi G, Meara A, Özgüler Y, Direskeneli H, Mahr A, Shea B, et al.; Outcome Measures in Rheumatology Behçet’s Syndrome Working Group. Core set of domains for outcome measures in Behçet’s syndrome. Arthritis Care Res (Hoboken). 2022;74(4):691-699. doi: 10.1002/acr.24511